Standout Papers

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease 2020 2026 2022 2024467
  1. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease (2020)
    Robert Zeiser, Nikolas von Bubnoff et al. New England Journal of Medicine

Immediate Impact

1 by Nobel laureates 37 from Science/Nature 61 standout
Sub-graph 1 of 21

Citing Papers

Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
2021 Standout
Therapeutic options in VEXAS syndrome: insights from a retrospective series
2021 Standout
1 intermediate paper

Works of Nikolas von Bubnoff being referenced

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
2020 Standout
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
2018
and 1 more

Author Peers

Author Last Decade Papers Cites
Nikolas von Bubnoff 1933 1309 1077 1102 134 4.0k
Ali G. Turhan 1990 1363 1020 1497 181 3.9k
Marc Loriaux 2158 2060 796 1956 96 4.5k
Philippe Martiat 1520 1416 1301 2007 109 5.5k
Ronald Paquette 3179 2321 596 1509 117 4.9k
Michael H. Tomasson 1786 652 1230 1608 115 3.5k
Philipp Erben 1964 1741 625 804 159 3.7k
Steffen Koschmieder 2344 1651 714 2719 219 5.1k
Ramón V. Tiu 3450 1980 544 2208 159 5.0k
Juan Luis Garcı́a 1202 820 970 1254 127 3.2k
Preetesh Jain 1376 2050 973 618 179 3.4k

All Works

Loading papers...

Rankless by CCL
2026